Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Feb 6, 2009 (rev. 1)

Premium

Stephen Friend will be leaving his position as executive vice president and franchise head of Merck Research Laboratories' oncology division later this year to "lead an effort to build open-access integrative bionetworks, or complex databases, whereby scientific researchers around the world can collaborate on disease representations to advance collective scientific knowledge," Merck said in a statement.

Gary Gilliland, a professor of medicine at Harvard Medical School and professor of stem cell and regenerative biology at Harvard University, will take on Friend's duties. He will step into his new role on March 2

The goal of Friend's effort will be to "leverage collaboration to accelerate the elimination of human disease," Merck said.

Friend, who co-founded Rosetta Inpharmatics in 1996 and joined Merck after it acquired Rosetta in 2001, declined to provide further information about his plans at this time.

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.